Meet IAG’s Bio-Partnering Team at BIO Digital 2021
IAG’s team will be attending Bio Digital, 14-18 June 2021, to meet clinical stage biotech companies developing novel treatments to address unmet patients’ needs.
IAG’s Bio-Partnering team is focused on building a diversified portfolio of innovative life science companies at various stages of clinical development. By bringing strategic collaborators and smart investments, we support novel drug or technology development efforts through conceptualisation, clinical trials to market entry.
Collaboratively, with the best academics of our time we are building mechanisms for early visibility of study performance through our DYNAMIKA platform. When needed and at the right time, our venture partners and analysts support development of the tailored strategies for potential M&As.
‘Our portfolio companies take full advantage of a wide range of IAG’s innovative R&D solutions, operational breadth and expertise, risk-sharing financing and partnership models’, added Dr. Olga Kubassova, CEO of IAG.
We directly invest or provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs. Therapeutic area focus: oncology, immunology, rheumatology / musculoskeletal, rare diseases, neuro-degenerative and neuroscience.
More on our recent partnerships can be found here: https://www.ia-grp.com/trial-solutions/bio-partnering/
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: email@example.com
Follow the Company: Linkedin
Drug development ideas in osteoarthritis, psoriatic arthritis and scleroderma.
The Invitation-only network for founders &CEOs of the most successful scaleups.
Dr Kubassova is a leading innovator and passionate investor in healthcare.
Presenting new data from Ulcerative Colitis trial at DDW 2023.